Economists warn NICE may be ill-prepared for value-based pricing plan.
NICE too readily blocks access to new drugs and lacks research expertise needed to support value-based pricing, health economists have argued.
A report by the University of York's Centre for Health Economics (CHE) said NICE underuses the option of backing a drug's use 'only in research'.
NICE currently has at least four options when assessing new technologies: reject, approve, approve only in research and approve with research. But NICE rarely recommends approval only in research or with research, the CHE said.
When value-based pricing is introduced, restricted approvals will …